Gut GVHD biomarker study for transplant patients
Part of Blood & lymphatic, Cancer clinical trials.
This trial aims to develop a test using multiple biomarkers to predict how well patients will respond to treatment for acute graft-versus-host disease (GVHD) affecting the gut. It focuses on patients who are receiving an allogeneic stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 12 years old.
- You must be scheduled to receive an allogeneic stem cell transplant (a transplant from a donor).
- You or your guardian must sign a consent form to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at two blood markers to predict the risk of acute graft-versus-host disease after an allogeneic stem cell transplant. If you qualify, your care team may use results to help anticipate and manage complications earlier.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
This trial tests a combination of four medicines (cyclophosphamide, abatacept, vedolizumab, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant for children and young adults with certain blood cancers. The goal is to see if this approach reduces the risk of GVHD, a serious complication where donor cells attack the body.
This study looks for proteins or markers in your blood that could help predict a condition called chronic graft-versus-host disease (cGVHD), a common complication after a stem cell transplant from a donor. By joining, you may help doctors detect and treat this condition earlier.
This Phase 1 study tests a new combination of medicines to prevent graft-versus-host disease (GVHD) after an allogeneic stem cell transplant. If it works well, it may lower the chance and severity of GVHD, which can affect skin, liver, and the gut.
This trial tests adding ruxolitinib to standard drugs (tacrolimus and methotrexate) to prevent graft-versus-host disease in children and young adults undergoing a stem cell transplant for acute leukemia or myelodysplastic syndrome. The goal is to lower the risk of GVHD and improve transplant outcomes.
Hear when a new Blood Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.